Table 1 Study design and methodology
Characteristic | Schedule |
|---|---|
No. of animals | 25 males/25 females |
Groups | low-dose, mid-dose, high-dose, Ad5-null, and vehicle control group |
Subcutaneous injection | Weekly × 7 |
Day killed | Days 46 and 71 |
Clinical signs | Twice daily |
Body weight and temperature | Twice before injection, weekly after dosing |
ECG | Pre-injection, day 44, and day 67 |
Clinical pathology (hematology, serum chemistry) | Pre-injection, day 21, day 44, and day 67 |
Serum IFN-γ | Pre-injection, day 7, day 35, day 45, and day 68 |
Lymphocyte subsets | Pre-injection, day 3, day 10, day 45, and day 68 |
Serum anti-Ad antibody, neutralizing antibody | Pre-injection, day 7, day 21, day 45, and day 68 |
Systemic autopsy, organ weight, histopathology | Day 46 and day 71 |
Hepatic IFN-γ, TNF-α, and IL-2 |